Home / DSC127 / Development Plan

A Phase II Study on the healing of Diabetic Foot Ulcers is expected to be completed in 2010, paving the way for a pivotal study and potentially the first new drug for Diabetic Foot Ulcers since 1997.

DSC127 has been shown in preclinical studies to significantly improve healing rates and to reduce scarring. Indications being considered include:

  • Diabetic Foot Ulcers
  • Venous Leg Ulcers
  • Arterial Ulcers
  • Pressure Ulcers
  • Burns (Thermal & Chemical)
  • Scar Prevention

Currently, DSC127 is in various stages of two clinical development programs: